SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sight Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.26−0.02 (-0.24%)
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
86.2%+19.5 pts over 5 years
Operating margin
-48.0%+68.5 pts over 5 years
Net margin
-49.7%+75.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -3.1% | +2.7% | +22.9% | – | |
| Gross profit | -2.4% | +4.2% | +29.3% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 48.3% | -50.7% | |
| Return on assets | – | – | -29.8% | |
| Current ratio | – | 7.58 | 10.22 | |
| Debt to equity | – | -0.36 | 0.63 | |
| Net debt to EBITDA | – | – | 1.41× | |
| Interest coverage | – | -13.4× | -7.2× | |
| Inventory turnover | – | – | 1.5× | |
| Capex to revenue | – | 3.4% | 0.3% | |
| Diluted shares | – | 9M | 52M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sight Sciences generated $227.73M from operations and spent $3.18M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$227.73M
Used
$3.18M
Capital expenditure$3.18M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-49.7%
×Asset turnover0.60×
×Equity multiplier1.70×
=Return on equity, FY2025-50.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -49.7% | 0.60× | 1.70× | -50.7% |
| FY2024 | -64.5% | 0.52× | 1.49× | -49.6% |
| FY2023 | -68.5% | 0.43× | 1.35× | -39.6% |
| FY2022 | -120.9% | 0.29× | 1.26× | -44.0% |
| FY2021 | -128.6% | 0.28× | 2.46× | -87.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$38.43M
- Cash generatingOperating cash flow above zero-$29.69M
- Return on assets improvedROA up on the prior year-30.9% → -26.9%
- Earnings backed by cashOperating cash flow above net income-$29.69M vs -$38.43M
- Less leverageLong-term debt to assets fell27.6% → 35.0%
- Better liquidityCurrent ratio rose9.04 → 10.22
- No dilutionShare count did not rise50M → 52M
- Gross margin improvedGross margin up on the prior year85.50% → 86.17%
- More efficientAsset turnover rose0.48 → 0.54